Kinoshita et al. 2014 48 patients (from same clinic as above and largely overlapping time period). 18 fulfilling the diagnostic criteria for CRPS-1. Abstract /Kinoshita et al, 2014 17 patients from an unknown time period. -Kinoshita et al, 2014 17 patients from an unknown time period. Letter to the editor / 2 adolescents Both patients fulfilled the fibromyalgia criteria and were 22 Richards et ...

Preventive anti-HPV vaccines are effective against HPV infection but not against existing HPV-associated diseases, including cervical cancer and other malignant diseases. Therefore, the development of therapeutic vaccines is urgently needed. To improve anti-tumor effects of therapeutic vaccine, we fused cytotoxic T-lymphocyte antigen 4 (CTLA-4) with HPV16 E7 and E6 as a fusion therapeutic DNA v...

Vaccines prophylactic against infection with human papillomavirus (HPV) are based on alum adjuvanted virus-like particles. Two such vaccines have recently been shown to prevent persistent HPV infection and associated cervical cancer precursor lesions. The genotype-specific neutralising antibody directed at conformational epitopes of the L1 major capsid protein is likely to mediate protection. V...

of IBD patients (Table 1.7-8) These guidelines recommend against the use of live vaccines in patients on immunosuppressive medications, but encourage the use of non-live vaccines, such as the HPV vaccine. The HPV vaccine is one of the recommended vaccines for patients with IBD. HPV affects approximately 20 million Americans. Most HPV infections are transient and asymptomatic, but certain Immuno...

BACKGROUND Vaccines based on virus-like particles are effective against Human Papilloma Virus (HPV) infection; however, they have not shown a therapeutic effect against HPV-associated diseases. New immunotherapy strategies based on immune responses against tumor antigens can positively affect the clearance of HPV-associated lesions. OBJECTIVE To generate two therapeutic fusion DNA vaccines (o...

Human Papillomavirus (HPV) is the most common sexually transmitted disease which can infect different parts of the body including uterus. Cervical cancer is the second most common cancer among women worldwide. In 2008, Zur Hausen received the Nobel Prize in “Medicine or Physiology” for proving the causative link between HPV and cervical cancer research. The HPV-related disease appears to be inc...

Multivalent prophylactic human papillomavirus (HPV) vaccines currently in the late stages of clinical testing are safe, immunogenic, and efficacious; and phase 3 tests of a quadrivalent vaccine show that it is 100% effective at preventing HPV types 16 and 18-associated cervical intraepithelial neoplasia grades 2 and 3, adenocarcinoma in situ, and cervical cancer through 2 years of postvaccinati...

OBJECTIVE To analyze organizational correlates of immunization coverage among adolescents served by high-volume primary care providers in North Carolina. METHODS We randomly selected 91 clinics with at least 200 active records for patients ages 11-18 in the North Carolina Immunization Registry. For the 105,121 adolescents served by these clinics, we obtained immunization status for 6 vaccines...

A new and very promising approach in vaccine development is the application of naked DNA. In comparison to conventional vaccines it offers several advantages, especially if there is a need for the development of low cost vaccines. Infection with high-risk human papillomaviruses (hr-HPVs) is the major risk factor for the development of cervical cancer (cc), the third most common cancer in women ...

Human papillomavirus (HPV) is a well-known sexually transmitted disorder globally. the 3rd most common cancer that causes cervical carcinoma, and globally it accounts for 275,000 deaths every year. The load of HPV-associated abrasions can be lessened through vaccination. At present, three forms prophylactic vaccines, Cervarix, Gadrasil, Gardasil 9, are commercially accessible but all these vacc...